Agentix Corp AGTX
Trading Information
- Previous Close Price
- $0.02
- Day Range
- $0.02–0.04
- 52-Week Range
- $0.01–0.06
- Bid/Ask
- $0.02 / $0.04
- Shares Outstanding
- 40.07M
- Market Cap
- $801,339.02
- Volume/Avg
- 188,737 / 53,443
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Agentix Corp is a biotechnology company. Through its subsidiary, it is engaged in the development and commercialization of novel therapeutics to treat metabolic diseases, peripheral neuropathy, progressive lung disease, and ischemic reperfusion injury. Its principal business objective is to develop both science-driven synthetic and natural cannabinoid therapeutics that address unmet medical needs and continue to drive innovations in the endocannabinoid space. Its pipeline of drug candidates includes AGTX-2004, a CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus (T2DM), and AGTX-2003 a peripherally-acting CB1 receptor inverse agonist that has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 0
- Website
- https://www.agentixcorp.com
Valuation
|
Metric
|
AGTX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
AGTX
Financial Strength
|
Metric
|
AGTX
|
|---|---|
Quick Ratio | 0.00 |
Current Ratio | 0.00 |
Interest Coverage | −4.15 |
Quick Ratio
AGTX
Profitability
|
Metric
|
AGTX
|
|---|---|
Return on Assets (Normalized) | −12,123.53% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
AGTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|S&Tms!# | LOCK|@YG$ | $131B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%!<k&^ | LOCK|^Cbyv | $83B | |||
| argenx SE ADR
ARGX
| LOCK|Y%bG!v | LOCK|s%? | $54B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Pcv<hqLZ | LOCK|P$DCw | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|^RvZvn | LOCK|<!Z | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Sm!#NGb | LOCK|phsP | $30B | |||
| Moderna Inc
MRNA
| LOCK|%LT<Q$> | LOCK|nwl | $25B | |||
| Incyte Corp
INCY
| LOCK|mnN>@yc | LOCK|%?v | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|cT?q?> | LOCK|KM! | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|g$kMsD | LOCK|qNw | $16B |
United States